CapsoVision (CV) Accumulated Expenses (2024 - 2025)

CapsoVision's (CV) quarterly Accumulated Expenses came in at $2.7 million in Q4 2025, up 373.99% year-on-year from $569000.0 in Q4 2024, and down 3.33% quarter-over-quarter from $2.8 million in Q3 2025.

CapsoVision (CV) Accumulated Expenses (2024 - 2025) Analysis & Trends

CapsoVision has disclosed Accumulated Expenses across 2 years of filings, most recently posting $2.7 million for Q4 2025.

  • Accumulated Expenses for Q4 2025 came in at $2.7 million, up 373.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.7 million (up 373.99% YoY), and the FY2025 annual result was $2.7 million, up 373.99% from the prior year.
  • Accumulated Expenses came in at $2.7 million for Q4 2025 at CapsoVision, down from $2.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.8 million in Q3 2025 to a low of $569000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.92 Bn 146.27 Bn 6.27 Bn
2 Stryker 119.50 Bn 116.62 Bn 3.81 Bn
3 Medtronic 102.71 Bn 94.54 Bn 5.76 Bn
4 Boston Scientific 69.72 Bn 68.51 Bn 3.61 Bn
5 Edwards Lifesciences 49.24 Bn 45.57 Bn 1.29 Bn
6 GE HealthCare Technologies 29.74 Bn 27.67 Bn 1.98 Bn
7 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
8 Dexcom 28.96 Bn 27.84 Bn 750.30 Mn
9 Steris 20.31 Bn 19.88 Bn 697.10 Mn
10 CapsoVision 176.55 Mn 166.44 Mn 1.95 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 2.70 Mn
Sep 30, 2025 2.79 Mn
Jun 30, 2025 1.59 Mn
Dec 31, 2024 569,000.00